# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA3705101 | B | Activity Assay: The primary assay for compound inhibitory activity was the ATP depletion assay using the PDKtide substrate purchase from Millipore Corporation. | Homo sapiens | 21 | single protein format | BindingDB Database | ||
2. | ALA3705102 | B | Binding Assay: The secondary assay was a time resolved-FRET LanthaScreen Kinase Binding Assay. (Invitrogen Corporation, Carlsbad, Calif.). This assay evaluates the ability of the test compound to compete with a fluorescently-labeled tracer molecule to bind in the ATP pocket of a kinase. | Homo sapiens | 19 | single protein format | BindingDB Database | ||
3. | ALA4220018 | B | Inhibition of PDK1 (unknown origin) after 1 hr in presence of Ser/Thr-07 by fluorometric assay | Homo sapiens | 26 | single protein format | Scientific Literature | ||
4. | ALA4220019 | B | Inhibition of p70S6K (unknown origin) at 500 nM | Homo sapiens | 1 | protein format | Scientific Literature | ||
5. | ALA4220020 | B | Inhibition of VEGFR1 (unknown origin) at 500 nM | Homo sapiens | 1 | single protein format | Scientific Literature | ||
6. | ALA4220021 | B | Inhibition of VEGFR2 (unknown origin) at 500 nM | Homo sapiens | 1 | single protein format | Scientific Literature | ||
7. | ALA4220022 | B | Inhibition of PDGFRA (unknown origin) at 500 nM | Homo sapiens | 1 | single protein format | Scientific Literature | ||
8. | ALA4220023 | F | Antiproliferative activity against human AN3CA cells harboring PTEN/PIK3R1 double mutant after 96 hrs by ATP lite assay | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
9. | ALA4220024 | F | Antiproliferative activity against human RL95-2 cells harboring PTEN/HRAS double mutant after 96 hrs by ATP lite assay | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
10. | ALA4220025 | F | Antiproliferative activity against human Hec1A cells harboring PIK3CA mutant after 96 hrs by ATP lite assay | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
11. | ALA4220026 | F | Antiproliferative activity against human Hs578T cells harboring PIK3R1 mutant in presence of PTEN shRNA after 96 hrs by ATP lite assay | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
12. | ALA4220027 | B | Inhibition of PDK1 mediated PI3K/Akt/mTOR pathway activation in human AN3CA cells assessed as reduction in AKT phosphorylation at Thr308 residue at 100 nM after 24 hrs by Meso Scale Discovery assay | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
13. | ALA4220028 | B | Inhibition of PDK1 mediated PI3K/Akt/mTOR pathway activation in human AN3CA cells assessed as reduction in ribosomal p70S6 protein phosphorylation after 2 hrs by in-cell Western blotting analysis | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
14. | ALA4220029 | B | Inhibition of PDK1 mediated PI3K/Akt/mTOR pathway activation in human AN3CA cells assessed as reduction in AKT phosphorylation at Thr308 residue after 24 hrs by Meso Scale Discovery assay | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
15. | ALA4220030 | F | Antiproliferative activity against human IOMM-Lee cells | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
16. | ALA4220031 | F | Antiproliferative activity against human MDA-MB-231 cells | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
17. | ALA4220032 | F | Antiproliferative activity against human KG1 cells | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
18. | ALA4220033 | F | Antiproliferative activity against human MV4-11 cells | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
19. | ALA4220034 | F | Antiproliferative activity against human KATO III cells | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
20. | ALA4220035 | F | Antiproliferative activity against human Kasumi-1 cells | Homo sapiens | 2 | cell-based format | Scientific Literature |